Injectable Therapy for Diabetes Mellitus: Glucagon-Like Peptide-1 Receptor Agonist
10.4093/jkd.2019.20.3.149
- Author:
Inkuk LEE
1
;
Eun Seok KANG
Author Information
1. Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea. edgo@yuhs.ac
- Publication Type:Original Article
- Keywords:
Cardiovascular diseases;
Diabetes mellitus;
Glucagon-like peptide-1;
Kidney diseases;
Obesity
- MeSH:
Body Weight;
Cardiovascular Diseases;
Diabetes Mellitus;
Glucagon-Like Peptide 1;
Glucagon-Like Peptide-1 Receptor;
Glucose;
Humans;
Hypoglycemia;
Incidence;
Kidney Diseases;
Liraglutide;
Myocardial Infarction;
Obesity;
Renal Insufficiency, Chronic;
Stroke;
Weight Loss
- From:Journal of Korean Diabetes
2019;20(3):149-156
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
According to the American Diabetes Association (ADA) and the European Association for the Study of Diabetes guideline for treatment of diabetes, glucagon-like peptide-1 receptor agonist (GLP-1 RA) is recommended in diabetic patients with established atherosclerotic cardiovascular disease. This recommendation is based on the results of recent cardiovascular outcome trials of this kind of medications. GLP-1 RAs have a glucose lowering effect with weight loss and a lower incidence of hypoglycemia, and can improve cardiovascular outcomes such as three-point major cardiovascular events composed of death from cardiovascular causes, non-fatal myocardial infarction, and non-fatal stroke. Also, several GLP-1 RAs have beneficial effects on renal outcomes, mainly due to improvement in macroalbuminuria. In addition, high-dose liraglutide (3 mg/day subcutaneous injection) showed efficacy for reducing body weight. Therefore GLP-1 RA may be effective in patients with established cardiovascular disease, chronic kidney disease, and/or metabolic syndrome.
